非布司他治疗痛风的快速卫生技术评估

目的 基于快速卫生技术评估(HTA)方法,评价非布司他治疗痛风的有效性、安全性和经济性.方法 系统检索PubMed、Cochrane library等英文数据库和中国知网(CNKI)、万方数据等中文数据库.由2位评价者根据纳入与排除标准独立筛选文献、提取资料和评价质量后,对结果进行定性分析.结果 共纳入2篇HTA报告、...

Rapid health technology assessment of febuxostat in the treatment of gout

Objective To evaluate the efficacy,safety and economics of febuxostat in the treatment of gout by rapid health technology assessment(HTA).Methods The PubMed,Cochrane library,CNKI and Wanfang data were searched.Two reviewers independently screened studies,extracted data and assessed the quality of included studies,and the qualitative analysis was performed.Results Totally 2 HTA reports,3 systematic reviews/Meta-analysis and 3 pharmacoeconomic studies were included.Efficacy:40 mg febuxostat was similar to allopurinol,while 80 mg and 120 mg febuxostat were better than allopurinol in decrease level of serum uric acid at the last follow-up,the standard-reaching rate of serum uric acid concentration at the last follow-up and the proportion of patients who kept reaching standard in serum uric acid at the last 3 months of follow-up.Safety:40 mg febuxostat was similar to allopurinol,while 80 and 120 mg febuxostat was better than allopurinol in the incidence of adverse drug reaction.Febuxostat was similar to allopurinol in short-time use,while higher than allopurinol in long-time use in cardiovascular risk(P<0.05).Pharmacoeconomics:5 pharmacoeconomic studies implied that febuxostat was a cost-effective choice.Conclusion Febuxostat has good efficacy,safety and economic advantage in the treatment of gout compared with allopurinol/placebo.More primary studies should be conducted to improve the evidence system.